Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

NanoEcho

0.06 SEK

+3.57 %

Less than 1K followers

NANECH

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Investor consensus
Compare
+3.57 %
+0.17 %
-51.67 %
-21.62 %
-80.88 %
-57.64 %
-
-
-62.80 %

NanoEcho is active in healthcare, with a main focus in rectal cancer diagnostics. The company is active in the clinical stage, where a new diagnostic method is being developed to determine whether early rectal cancer has spread to nearby lymph nodes. The method aims to provide a correct diagnosis and individualized treatment. NanoEcho was founded in 2013 and has its headquarters in Lund.

Read more
Market cap
16.99M SEK
Turnover
36.58K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2.
2026

Annual report '25

30.4.
2026

Interim report Q1'26

28.5.
2026

General meeting '26

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.